Evidence of plasma biomarkers indicating high risk of dementia in cognitively normal subjects

Subjects with comorbidities are at risk for neurodegeneration. There is a lack of a direct relationship between comorbidities and neurodegeneration. In this study, immunomagnetic reduction (IMR) assays were utilized to assay plasma Aβ 1–42 and total tau protein (T-Tau) levels in poststroke (PS, n = ...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 12; no. 1; pp. 1192 - 7
Main Authors Pai, Ming-Chyi, Wu, Chau-Chung, Hou, Yi-Chou, Jeng, Jiann-Shing, Tang, Sung-Chun, Lin, Wei-Che, Lu, Cheng-Hsien, Chiu, Ming-Jang, Chen, Ta-Fu, Yan, Sui-Hing, Hu, Chaur-Jong, Yang, Shieh-Yueh
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 24.01.2022
Nature Publishing Group
Nature Portfolio
Subjects
631/378
692/499
692/53
692/617
692/699
Adult
Aged
Aged, 80 and over
Alzheimer's disease
Amyloid beta-Peptides - blood
Apnea
Biomarkers
Biomarkers - blood
Case-Control Studies
Cognition
Dementia
Dementia - blood
Dementia - etiology
Dementia disorders
Diabetes
Diabetes Complications - blood
Diabetes mellitus
End-stage renal disease
Female
Genetics
Humanities and Social Sciences
Humans
Kidney diseases
Kidney Failure, Chronic - blood
Kidney Failure, Chronic - complications
Male
Middle Aged
multidisciplinary
Neurodegeneration
Neurodegenerative diseases
Peptide Fragments - blood
Plasma
Plasma levels
Risk Assessment
Science
Science (multidisciplinary)
Sleep apnea
Sleep Apnea, Obstructive - blood
Sleep Apnea, Obstructive - complications
Sleep disorders
Stroke
Stroke - blood
Stroke - complications
Tau protein
tau Proteins - blood
Online AccessGet full text
ISSN2045-2322
2045-2322
DOI10.1038/s41598-022-05177-z

Cover

Abstract Subjects with comorbidities are at risk for neurodegeneration. There is a lack of a direct relationship between comorbidities and neurodegeneration. In this study, immunomagnetic reduction (IMR) assays were utilized to assay plasma Aβ 1–42 and total tau protein (T-Tau) levels in poststroke (PS, n = 27), family history of Alzheimer’s disease (ADFH, n = 35), diabetes (n = 21), end-stage renal disease (ESRD, n = 41), obstructive sleep apnea (OSA, n = 20), Alzheimer’s disease (AD, n = 65). Thirty-seven healthy controls (HCs) were enrolled. The measured concentrations of plasma Aβ 1–42 were 14.26 ± 1.42, 15.43 ± 1.76, 15.52 ± 1.60, 16.15 ± 1.05, 16.52 ± 0.59, 15.97 ± 0.54 and 20.06 ± 3.09 pg/mL in HC, PS, ADFH, diabetes, ESRD, OSA and AD groups, respectively. The corresponding concentrations of plasma T-Tau were 15.13 ± 3.62, 19.29 ± 8.01, 17.93 ± 6.26, 19.74 ± 2.92, 21.54 ± 2.72, 20.17 ± 2.77 and 41.24 ± 14.64 pg/mL. The plasma levels of Aβ 1–42 and T-Tau in were significantly higher in the PS, ADFH, diabetes, ESRD and OSA groups than controls (Aβ 1–42 in PS: 15.43 ± 1.76 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.005; T-Tau in PS: 19.29 ± 8.01 vs. 15.13 ± 3.62 pg/mL, p < 0.005, Aβ 1–42 in ADFH: 15.52 ± 1.60 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in ADFH: 17.93 ± 6.26 vs. 15.13 ± 3.62 pg/mL, p < 0.005, Aβ 1–42 in diabetes: 16.15 ± 1.05 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in diabetes: 19.74 ± 2.92 vs. 15.13 ± 3.62 pg/mL, p < 0.001, Aβ 1–42 in ESRD: 16.52 ± 0.59 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in ESRD: 21.54 ± 2.72 vs. 15.13 ± 3.62 pg/mL, p < 0.001, Aβ 1–42 in OSA: 15.97 ± 0.54 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in OSA: 20.17 ± 2.77 vs. 15.13 ± 3.62 pg/mL, p < 0.001). This evidence indicates the high risk for dementia in these groups from the perspective of plasma biomarkers.
AbstractList Abstract Subjects with comorbidities are at risk for neurodegeneration. There is a lack of a direct relationship between comorbidities and neurodegeneration. In this study, immunomagnetic reduction (IMR) assays were utilized to assay plasma Aβ1–42 and total tau protein (T-Tau) levels in poststroke (PS, n = 27), family history of Alzheimer’s disease (ADFH, n = 35), diabetes (n = 21), end-stage renal disease (ESRD, n = 41), obstructive sleep apnea (OSA, n = 20), Alzheimer’s disease (AD, n = 65). Thirty-seven healthy controls (HCs) were enrolled. The measured concentrations of plasma Aβ1–42 were 14.26 ± 1.42, 15.43 ± 1.76, 15.52 ± 1.60, 16.15 ± 1.05, 16.52 ± 0.59, 15.97 ± 0.54 and 20.06 ± 3.09 pg/mL in HC, PS, ADFH, diabetes, ESRD, OSA and AD groups, respectively. The corresponding concentrations of plasma T-Tau were 15.13 ± 3.62, 19.29 ± 8.01, 17.93 ± 6.26, 19.74 ± 2.92, 21.54 ± 2.72, 20.17 ± 2.77 and 41.24 ± 14.64 pg/mL. The plasma levels of Aβ1–42 and T-Tau in were significantly higher in the PS, ADFH, diabetes, ESRD and OSA groups than controls (Aβ1–42 in PS: 15.43 ± 1.76 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.005; T-Tau in PS: 19.29 ± 8.01 vs. 15.13 ± 3.62 pg/mL, p < 0.005, Aβ1–42 in ADFH: 15.52 ± 1.60 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in ADFH: 17.93 ± 6.26 vs. 15.13 ± 3.62 pg/mL, p < 0.005, Aβ1–42 in diabetes: 16.15 ± 1.05 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in diabetes: 19.74 ± 2.92 vs. 15.13 ± 3.62 pg/mL, p < 0.001, Aβ1–42 in ESRD: 16.52 ± 0.59 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in ESRD: 21.54 ± 2.72 vs. 15.13 ± 3.62 pg/mL, p < 0.001, Aβ1–42 in OSA: 15.97 ± 0.54 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in OSA: 20.17 ± 2.77 vs. 15.13 ± 3.62 pg/mL, p < 0.001). This evidence indicates the high risk for dementia in these groups from the perspective of plasma biomarkers.
Subjects with comorbidities are at risk for neurodegeneration. There is a lack of a direct relationship between comorbidities and neurodegeneration. In this study, immunomagnetic reduction (IMR) assays were utilized to assay plasma Aβ 1–42 and total tau protein (T-Tau) levels in poststroke (PS, n = 27), family history of Alzheimer’s disease (ADFH, n = 35), diabetes (n = 21), end-stage renal disease (ESRD, n = 41), obstructive sleep apnea (OSA, n = 20), Alzheimer’s disease (AD, n = 65). Thirty-seven healthy controls (HCs) were enrolled. The measured concentrations of plasma Aβ 1–42 were 14.26 ± 1.42, 15.43 ± 1.76, 15.52 ± 1.60, 16.15 ± 1.05, 16.52 ± 0.59, 15.97 ± 0.54 and 20.06 ± 3.09 pg/mL in HC, PS, ADFH, diabetes, ESRD, OSA and AD groups, respectively. The corresponding concentrations of plasma T-Tau were 15.13 ± 3.62, 19.29 ± 8.01, 17.93 ± 6.26, 19.74 ± 2.92, 21.54 ± 2.72, 20.17 ± 2.77 and 41.24 ± 14.64 pg/mL. The plasma levels of Aβ 1–42 and T-Tau in were significantly higher in the PS, ADFH, diabetes, ESRD and OSA groups than controls (Aβ 1–42 in PS: 15.43 ± 1.76 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.005; T-Tau in PS: 19.29 ± 8.01 vs. 15.13 ± 3.62 pg/mL, p < 0.005, Aβ 1–42 in ADFH: 15.52 ± 1.60 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in ADFH: 17.93 ± 6.26 vs. 15.13 ± 3.62 pg/mL, p < 0.005, Aβ 1–42 in diabetes: 16.15 ± 1.05 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in diabetes: 19.74 ± 2.92 vs. 15.13 ± 3.62 pg/mL, p < 0.001, Aβ 1–42 in ESRD: 16.52 ± 0.59 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in ESRD: 21.54 ± 2.72 vs. 15.13 ± 3.62 pg/mL, p < 0.001, Aβ 1–42 in OSA: 15.97 ± 0.54 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in OSA: 20.17 ± 2.77 vs. 15.13 ± 3.62 pg/mL, p < 0.001). This evidence indicates the high risk for dementia in these groups from the perspective of plasma biomarkers.
Subjects with comorbidities are at risk for neurodegeneration. There is a lack of a direct relationship between comorbidities and neurodegeneration. In this study, immunomagnetic reduction (IMR) assays were utilized to assay plasma Aβ1–42 and total tau protein (T-Tau) levels in poststroke (PS, n = 27), family history of Alzheimer’s disease (ADFH, n = 35), diabetes (n = 21), end-stage renal disease (ESRD, n = 41), obstructive sleep apnea (OSA, n = 20), Alzheimer’s disease (AD, n = 65). Thirty-seven healthy controls (HCs) were enrolled. The measured concentrations of plasma Aβ1–42 were 14.26 ± 1.42, 15.43 ± 1.76, 15.52 ± 1.60, 16.15 ± 1.05, 16.52 ± 0.59, 15.97 ± 0.54 and 20.06 ± 3.09 pg/mL in HC, PS, ADFH, diabetes, ESRD, OSA and AD groups, respectively. The corresponding concentrations of plasma T-Tau were 15.13 ± 3.62, 19.29 ± 8.01, 17.93 ± 6.26, 19.74 ± 2.92, 21.54 ± 2.72, 20.17 ± 2.77 and 41.24 ± 14.64 pg/mL. The plasma levels of Aβ1–42 and T-Tau in were significantly higher in the PS, ADFH, diabetes, ESRD and OSA groups than controls (Aβ1–42 in PS: 15.43 ± 1.76 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.005; T-Tau in PS: 19.29 ± 8.01 vs. 15.13 ± 3.62 pg/mL, p < 0.005, Aβ1–42 in ADFH: 15.52 ± 1.60 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in ADFH: 17.93 ± 6.26 vs. 15.13 ± 3.62 pg/mL, p < 0.005, Aβ1–42 in diabetes: 16.15 ± 1.05 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in diabetes: 19.74 ± 2.92 vs. 15.13 ± 3.62 pg/mL, p < 0.001, Aβ1–42 in ESRD: 16.52 ± 0.59 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in ESRD: 21.54 ± 2.72 vs. 15.13 ± 3.62 pg/mL, p < 0.001, Aβ1–42 in OSA: 15.97 ± 0.54 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in OSA: 20.17 ± 2.77 vs. 15.13 ± 3.62 pg/mL, p < 0.001). This evidence indicates the high risk for dementia in these groups from the perspective of plasma biomarkers.
Subjects with comorbidities are at risk for neurodegeneration. There is a lack of a direct relationship between comorbidities and neurodegeneration. In this study, immunomagnetic reduction (IMR) assays were utilized to assay plasma Aβ1-42 and total tau protein (T-Tau) levels in poststroke (PS, n = 27), family history of Alzheimer's disease (ADFH, n = 35), diabetes (n = 21), end-stage renal disease (ESRD, n = 41), obstructive sleep apnea (OSA, n = 20), Alzheimer's disease (AD, n = 65). Thirty-seven healthy controls (HCs) were enrolled. The measured concentrations of plasma Aβ1-42 were 14.26 ± 1.42, 15.43 ± 1.76, 15.52 ± 1.60, 16.15 ± 1.05, 16.52 ± 0.59, 15.97 ± 0.54 and 20.06 ± 3.09 pg/mL in HC, PS, ADFH, diabetes, ESRD, OSA and AD groups, respectively. The corresponding concentrations of plasma T-Tau were 15.13 ± 3.62, 19.29 ± 8.01, 17.93 ± 6.26, 19.74 ± 2.92, 21.54 ± 2.72, 20.17 ± 2.77 and 41.24 ± 14.64 pg/mL. The plasma levels of Aβ1-42 and T-Tau in were significantly higher in the PS, ADFH, diabetes, ESRD and OSA groups than controls (Aβ1-42 in PS: 15.43 ± 1.76 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.005; T-Tau in PS: 19.29 ± 8.01 vs. 15.13 ± 3.62 pg/mL, p < 0.005, Aβ1-42 in ADFH: 15.52 ± 1.60 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in ADFH: 17.93 ± 6.26 vs. 15.13 ± 3.62 pg/mL, p < 0.005, Aβ1-42 in diabetes: 16.15 ± 1.05 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in diabetes: 19.74 ± 2.92 vs. 15.13 ± 3.62 pg/mL, p < 0.001, Aβ1-42 in ESRD: 16.52 ± 0.59 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in ESRD: 21.54 ± 2.72 vs. 15.13 ± 3.62 pg/mL, p < 0.001, Aβ1-42 in OSA: 15.97 ± 0.54 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in OSA: 20.17 ± 2.77 vs. 15.13 ± 3.62 pg/mL, p < 0.001). This evidence indicates the high risk for dementia in these groups from the perspective of plasma biomarkers.Subjects with comorbidities are at risk for neurodegeneration. There is a lack of a direct relationship between comorbidities and neurodegeneration. In this study, immunomagnetic reduction (IMR) assays were utilized to assay plasma Aβ1-42 and total tau protein (T-Tau) levels in poststroke (PS, n = 27), family history of Alzheimer's disease (ADFH, n = 35), diabetes (n = 21), end-stage renal disease (ESRD, n = 41), obstructive sleep apnea (OSA, n = 20), Alzheimer's disease (AD, n = 65). Thirty-seven healthy controls (HCs) were enrolled. The measured concentrations of plasma Aβ1-42 were 14.26 ± 1.42, 15.43 ± 1.76, 15.52 ± 1.60, 16.15 ± 1.05, 16.52 ± 0.59, 15.97 ± 0.54 and 20.06 ± 3.09 pg/mL in HC, PS, ADFH, diabetes, ESRD, OSA and AD groups, respectively. The corresponding concentrations of plasma T-Tau were 15.13 ± 3.62, 19.29 ± 8.01, 17.93 ± 6.26, 19.74 ± 2.92, 21.54 ± 2.72, 20.17 ± 2.77 and 41.24 ± 14.64 pg/mL. The plasma levels of Aβ1-42 and T-Tau in were significantly higher in the PS, ADFH, diabetes, ESRD and OSA groups than controls (Aβ1-42 in PS: 15.43 ± 1.76 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.005; T-Tau in PS: 19.29 ± 8.01 vs. 15.13 ± 3.62 pg/mL, p < 0.005, Aβ1-42 in ADFH: 15.52 ± 1.60 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in ADFH: 17.93 ± 6.26 vs. 15.13 ± 3.62 pg/mL, p < 0.005, Aβ1-42 in diabetes: 16.15 ± 1.05 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in diabetes: 19.74 ± 2.92 vs. 15.13 ± 3.62 pg/mL, p < 0.001, Aβ1-42 in ESRD: 16.52 ± 0.59 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in ESRD: 21.54 ± 2.72 vs. 15.13 ± 3.62 pg/mL, p < 0.001, Aβ1-42 in OSA: 15.97 ± 0.54 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in OSA: 20.17 ± 2.77 vs. 15.13 ± 3.62 pg/mL, p < 0.001). This evidence indicates the high risk for dementia in these groups from the perspective of plasma biomarkers.
Subjects with comorbidities are at risk for neurodegeneration. There is a lack of a direct relationship between comorbidities and neurodegeneration. In this study, immunomagnetic reduction (IMR) assays were utilized to assay plasma Aβ and total tau protein (T-Tau) levels in poststroke (PS, n = 27), family history of Alzheimer's disease (ADFH, n = 35), diabetes (n = 21), end-stage renal disease (ESRD, n = 41), obstructive sleep apnea (OSA, n = 20), Alzheimer's disease (AD, n = 65). Thirty-seven healthy controls (HCs) were enrolled. The measured concentrations of plasma Aβ were 14.26 ± 1.42, 15.43 ± 1.76, 15.52 ± 1.60, 16.15 ± 1.05, 16.52 ± 0.59, 15.97 ± 0.54 and 20.06 ± 3.09 pg/mL in HC, PS, ADFH, diabetes, ESRD, OSA and AD groups, respectively. The corresponding concentrations of plasma T-Tau were 15.13 ± 3.62, 19.29 ± 8.01, 17.93 ± 6.26, 19.74 ± 2.92, 21.54 ± 2.72, 20.17 ± 2.77 and 41.24 ± 14.64 pg/mL. The plasma levels of Aβ and T-Tau in were significantly higher in the PS, ADFH, diabetes, ESRD and OSA groups than controls (Aβ in PS: 15.43 ± 1.76 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.005; T-Tau in PS: 19.29 ± 8.01 vs. 15.13 ± 3.62 pg/mL, p < 0.005, Aβ in ADFH: 15.52 ± 1.60 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in ADFH: 17.93 ± 6.26 vs. 15.13 ± 3.62 pg/mL, p < 0.005, Aβ in diabetes: 16.15 ± 1.05 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in diabetes: 19.74 ± 2.92 vs. 15.13 ± 3.62 pg/mL, p < 0.001, Aβ in ESRD: 16.52 ± 0.59 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in ESRD: 21.54 ± 2.72 vs. 15.13 ± 3.62 pg/mL, p < 0.001, Aβ in OSA: 15.97 ± 0.54 pg/mL vs. 14.26 ± 1.42 pg/mL, p < 0.001; T-Tau in OSA: 20.17 ± 2.77 vs. 15.13 ± 3.62 pg/mL, p < 0.001). This evidence indicates the high risk for dementia in these groups from the perspective of plasma biomarkers.
ArticleNumber 1192
Author Jeng, Jiann-Shing
Lu, Cheng-Hsien
Chiu, Ming-Jang
Chen, Ta-Fu
Pai, Ming-Chyi
Yan, Sui-Hing
Tang, Sung-Chun
Wu, Chau-Chung
Hu, Chaur-Jong
Yang, Shieh-Yueh
Hou, Yi-Chou
Lin, Wei-Che
Author_xml – sequence: 1
  givenname: Ming-Chyi
  surname: Pai
  fullname: Pai, Ming-Chyi
  organization: Division of Behavioral Neurology, Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University
– sequence: 2
  givenname: Chau-Chung
  surname: Wu
  fullname: Wu, Chau-Chung
  organization: Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Department & Graduate Institute of Medical Education & Bioethics, College of Medicine, National Taiwan University
– sequence: 3
  givenname: Yi-Chou
  surname: Hou
  fullname: Hou, Yi-Chou
  organization: Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Department of Internal Medicine, Cardinal Tien Hospital, School of Medicine, Fu Jen Catholic University
– sequence: 4
  givenname: Jiann-Shing
  surname: Jeng
  fullname: Jeng, Jiann-Shing
  organization: Department of Neurology, National Taiwan University Hospital
– sequence: 5
  givenname: Sung-Chun
  surname: Tang
  fullname: Tang, Sung-Chun
  organization: Department of Neurology, National Taiwan University Hospital
– sequence: 6
  givenname: Wei-Che
  surname: Lin
  fullname: Lin, Wei-Che
  organization: Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine
– sequence: 7
  givenname: Cheng-Hsien
  surname: Lu
  fullname: Lu, Cheng-Hsien
  organization: Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine
– sequence: 8
  givenname: Ming-Jang
  surname: Chiu
  fullname: Chiu, Ming-Jang
  organization: Department of Neurology, National Taiwan University Hospital, Graduate Institute of Brain and Mind Sciences, College of Medicine, National Taiwan University, Department of Psychology, National Taiwan University, Graduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University
– sequence: 9
  givenname: Ta-Fu
  surname: Chen
  fullname: Chen, Ta-Fu
  organization: Department of Neurology, National Taiwan University Hospital
– sequence: 10
  givenname: Sui-Hing
  surname: Yan
  fullname: Yan, Sui-Hing
  organization: Department of Neurology, Far Eastern Memorial Hospital
– sequence: 11
  givenname: Chaur-Jong
  surname: Hu
  fullname: Hu, Chaur-Jong
  organization: Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Department of Neurology, Dementia Center, Shuang Ho Hospital, Taipei Medical University, Graduate Institute of Neural Regenerative Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei Neuroscience Institute, Taipei Medical University
– sequence: 12
  givenname: Shieh-Yueh
  surname: Yang
  fullname: Yang, Shieh-Yueh
  email: syyang@magqu.com
  organization: MagQu Co., Ltd
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35075194$$D View this record in MEDLINE/PubMed
BookMark eNp9kk1vFSEYhYmpsbX2D7gwk7hxM8o3w8bENFWbNHGjS0MYYOZyOwNXmLlJ--tl7rTadlE2EHjO4bzwvgZHIQYHwFsEPyJImk-ZIiabGmJcQ4aEqG9fgBMMKasxwfjowfoYnOW8hWUwLCmSr8AxYVAwJOkJ-H2x99YF46rYVbtB51FXrY-jTtcu5coH642efOirje83VfL5eiGtG12YvC5AZWIf_OT3bripQkyjHqo8t1tnpvwGvOz0kN3Z3XwKfn29-Hn-vb768e3y_MtVbRiFU81IiSOdJIYSgZC0DvG2RQgygUzbCk6N4BYbzq0WREDNJCcFbzG1S03kFFyuvjbqrdolX_LfqKi9OmzE1CudJm8Gp4wR1EKuEe8klYxq2FBkdUea5bbOFq_Pq9dubkdnTakz6eGR6eOT4Deqj3vViIZLJovBhzuDFP_MLk9q9Nm4YdDBxTkrzDHmrMFCFPT9E3Qb5xTKUx0o0jBMWaHePUz0L8r9LxagWQGTYs7Jdcr4qfxaXAL6QSGolp5Ra8-o0jPq0DPqtkjxE-m9-7MisopygUPv0v_Yz6j-Ar8w07o
CitedBy_id crossref_primary_10_1093_ndt_gfae259
crossref_primary_10_14336_AD_2024_0286
crossref_primary_10_1016_j_smrv_2023_101790
crossref_primary_10_1093_gerona_glae206
crossref_primary_10_1016_j_ncl_2023_02_004
crossref_primary_10_1002_brb3_2972
crossref_primary_10_1016_j_neurol_2023_08_006
crossref_primary_10_20340_vmi_rvz_2024_3_PSY_1
crossref_primary_10_1016_j_ortho_2023_100814
Cites_doi 10.1021/acschemneuro.1c00010
10.1021/cn500101j
10.1212/WNL.0000000000001991
10.4103/1673-5374.290898
10.1002/acn3.51195
10.1212/01.WNL.0000137040.64252.ED
10.1038/srep13917
10.3389/fnagi.2017.00226
10.1007/s00415-009-5396-8
10.3389/fnagi.2020.00212
10.1093/ageing/afu101
10.1186/s13195-019-0566-0
10.1016/j.sleep.2009.10.005
10.1001/archneurol.2008.565
10.1007/s13760-019-01112-8
10.1186/s12888-017-1366-3
10.1016/S1474-4422(06)70537-3
10.1016/j.maturitas.2016.07.007
10.1016/j.jalz.2007.04.381
10.3233/JAD-191092
10.1016/S0140-6736(05)67889-0
10.1016/S1474-4422(09)70236-4
10.1016/j.jamda.2016.10.014
10.1016/j.vetmic.2007.04.001
10.3389/fnagi.2021.657794
10.1016/j.neurobiolaging.2006.03.004
10.3390/diagnostics9020065
10.3233/JAD-2010-100456
10.3389/fnagi.2019.00222
10.1007/978-1-4939-7704-8_13
10.1016/j.apmr.2011.01.021
10.3233/JAD-170784
10.1109/TASC.2010.2087304
10.1016/S1474-4422(14)70136-X
10.1038/s41467-019-09030-2
10.1186/s12889-019-7027-3
10.1038/srep06446
10.1016/j.bbrc.2012.06.017
10.1186/1471-2458-13-1
10.1371/journal.pone.0196214
10.1007/s12017-018-8513-y
10.3390/nu8030144
10.3389/fnagi.2018.00175
10.1016/j.aca.2014.06.024
10.1053/j.ajkd.2019.05.017
10.1016/S0929-6646(09)60402-2
10.1093/brain/awaa054
ContentType Journal Article
Copyright The Author(s) 2022
2022. The Author(s).
The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2022
– notice: 2022. The Author(s).
– notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
Q9U
7X8
5PM
DOA
DOI 10.1038/s41598-022-05177-z
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
Science Database
ProQuest Biological Science
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
CrossRef

Publicly Available Content Database

MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 7
ExternalDocumentID oai_doaj_org_article_cc74d06a16f94954a0841daf380571fd
PMC8786959
35075194
10_1038_s41598_022_05177_z
Genre Research Support, Non-U.S. Gov't
Multicenter Study
Journal Article
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFPKN
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
AARCD
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
Q9U
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c540t-530759e93c437119de16bb110571cbb764c76d2c66da7370a5963e93b24d52943
IEDL.DBID AAJSJ
ISSN 2045-2322
IngestDate Wed Aug 27 01:15:12 EDT 2025
Thu Aug 21 18:38:46 EDT 2025
Fri Sep 05 12:41:41 EDT 2025
Wed Aug 13 07:02:28 EDT 2025
Thu Jan 02 22:54:35 EST 2025
Tue Jul 01 01:34:18 EDT 2025
Thu Apr 24 22:55:34 EDT 2025
Fri Feb 21 02:40:29 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2022. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540t-530759e93c437119de16bb110571cbb764c76d2c66da7370a5963e93b24d52943
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.nature.com/articles/s41598-022-05177-z
PMID 35075194
PQID 2622385245
PQPubID 2041939
PageCount 7
ParticipantIDs doaj_primary_oai_doaj_org_article_cc74d06a16f94954a0841daf380571fd
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8786959
proquest_miscellaneous_2622658277
proquest_journals_2622385245
pubmed_primary_35075194
crossref_citationtrail_10_1038_s41598_022_05177_z
crossref_primary_10_1038_s41598_022_05177_z
springer_journals_10_1038_s41598_022_05177_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-01-24
PublicationDateYYYYMMDD 2022-01-24
PublicationDate_xml – month: 01
  year: 2022
  text: 2022-01-24
  day: 24
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2022
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Chen (CR10) 2009; 108
Palmqvist (CR21) 2015; 85
Pesaresi (CR40) 2006; 27
Fox (CR14) 2014; 43
Brookmeyer (CR3) 2007; 3
McDonnell (CR5) 2011; 92
Lipnicki (CR12) 2017; 18
Cao (CR4) 2020; 73
Morbelli, Bauckneht (CR19) 2018; 1750
Lue (CR42) 2017; 9
Ferri (CR2) 2005; 366
Spallazzi (CR22) 2019; 119
Iuliano (CR8) 2019; 19
Canevelli (CR6) 2016; 8
Kim (CR27) 2014; 840
Lim (CR44) 2019; 10
De (CR39) 2020; 43
Chiu (CR43) 2021; 21
Kivipelto (CR9) 2006; 5
Pendlebury, Rothwell (CR45) 2009; 8
Drew (CR46) 2019; 74
Fan (CR31) 2018; 10
Chiu (CR29) 2011; 21
Tsai (CR17) 2018; 13
Bu (CR48) 2015; 5
Suppiah (CR20) 2019; 9
Oh (CR25) 2010; 21
Hou (CR34) 2021; 13
Zhou (CR37) 2012; 423
Norton (CR11) 2014; 13
Birkmann (CR26) 2007; 123
Tzen (CR30) 2014; 5
Mondello (CR28) 2014; 4
Norton (CR1) 2013; 13
Reimand (CR23) 2020; 7
Lue (CR36) 2019; 11
Xia (CR24) 2009; 66
Sibbett (CR13) 2017; 17
Jiao (CR49) 2020; 12
Tang (CR33) 2018; 20
Scarabino (CR15) 2016; 171
Hassan, Chen (CR16) 2021; 16
Tufik (CR47) 2010; 1
Ford (CR7) 2016; 92
Lin (CR32) 2019; 11
Assini (CR38) 2004; 63
Furukawa (CR18) 2010; 257
Chiu (CR35) 2020; 26
Teunissen (CR41) 2018; 62
CZJ Lim (5177_CR44) 2019; 10
J Reimand (5177_CR23) 2020; 7
LY Fan (5177_CR31) 2018; 10
SY Lin (5177_CR32) 2019; 11
CE Teunissen (5177_CR41) 2018; 62
ST Pendlebury (5177_CR45) 2009; 8
LF Lue (5177_CR36) 2019; 11
JH Chen (5177_CR10) 2009; 108
E Iuliano (5177_CR8) 2019; 19
M Spallazzi (5177_CR22) 2019; 119
L Zhou (5177_CR37) 2012; 423
F Jiao (5177_CR49) 2020; 12
MJ Chiu (5177_CR29) 2011; 21
DA Drew (5177_CR46) 2019; 74
AH Ford (5177_CR7) 2016; 92
ES Oh (5177_CR25) 2010; 21
A Assini (5177_CR38) 2004; 63
M Kivipelto (5177_CR9) 2006; 5
S Suppiah (5177_CR20) 2019; 9
DM Lipnicki (5177_CR12) 2017; 18
JS Kim (5177_CR27) 2014; 840
XL Bu (5177_CR48) 2015; 5
YC Hou (5177_CR34) 2021; 13
K Furukawa (5177_CR18) 2010; 257
RA Sibbett (5177_CR13) 2017; 17
Q Cao (5177_CR4) 2020; 73
C Fox (5177_CR14) 2014; 43
W Xia (5177_CR24) 2009; 66
S Mondello (5177_CR28) 2014; 4
PH Tsai (5177_CR17) 2018; 13
S Palmqvist (5177_CR21) 2015; 85
D Scarabino (5177_CR15) 2016; 171
E Birkmann (5177_CR26) 2007; 123
R Brookmeyer (5177_CR3) 2007; 3
LF Lue (5177_CR42) 2017; 9
MJ Chiu (5177_CR43) 2021; 21
SC Tang (5177_CR33) 2018; 20
WF De (5177_CR39) 2020; 43
S Norton (5177_CR11) 2014; 13
CP Ferri (5177_CR2) 2005; 366
MJ Chiu (5177_CR35) 2020; 26
KY Tzen (5177_CR30) 2014; 5
S Norton (5177_CR1) 2013; 13
H Hassan (5177_CR16) 2021; 16
M Pesaresi (5177_CR40) 2006; 27
S Morbelli (5177_CR19) 2018; 1750
M Canevelli (5177_CR6) 2016; 8
S Tufik (5177_CR47) 2010; 1
MN McDonnell (5177_CR5) 2011; 92
References_xml – volume: 21
  start-page: 1376
  year: 2021
  end-page: 1383
  ident: CR43
  article-title: Synergistic association between plasma Aβ and p-tau in Alzheimer's disease but not in Parkinson's disease or frontotemporal dementia
  publication-title: ACS Chem. Neurosci.
  doi: 10.1021/acschemneuro.1c00010
– volume: 171
  start-page: 250
  year: 2016
  end-page: 256
  ident: CR15
  article-title: Influence of family history of dementia in the development and progression of late-onset Alzheimer's disease
  publication-title: Neuropsychiatr. Genet.
– volume: 5
  start-page: 830
  year: 2014
  end-page: 836
  ident: CR30
  article-title: Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer’s disease
  publication-title: ACS Chem. Neurosci.
  doi: 10.1021/cn500101j
– volume: 85
  start-page: 1240
  year: 2015
  end-page: 1249
  ident: CR21
  article-title: Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000001991
– volume: 16
  start-page: 310
  year: 2021
  end-page: 311
  ident: CR16
  article-title: Hypoxia in Alzheimer's disease: Effects of hypoxia inducible factors
  publication-title: Neural Regen. Res.
  doi: 10.4103/1673-5374.290898
– volume: 7
  start-page: 2150
  year: 2020
  end-page: 2160
  ident: CR23
  article-title: Amyloid-β PET and CSF in an autopsy-confirmed cohort
  publication-title: Ann. Clin. Transl. Neurol.
  doi: 10.1002/acn3.51195
– volume: 63
  start-page: 828
  year: 2004
  end-page: 831
  ident: CR38
  article-title: Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment
  publication-title: Neurology
  doi: 10.1212/01.WNL.0000137040.64252.ED
– volume: 5
  start-page: 13917
  year: 2015
  ident: CR48
  article-title: Serum amyloid-beta levels are increased in patients with obstructive sleep apnea syndrome
  publication-title: Sci. Rep.
  doi: 10.1038/srep13917
– volume: 9
  start-page: 226
  year: 2017
  ident: CR42
  article-title: Plasma levels of Aβ42 and tau identified probable Alzheimer’s dementia: Findings in two cohorts
  publication-title: Front. Aging Neurosci.
  doi: 10.3389/fnagi.2017.00226
– volume: 257
  start-page: 721
  year: 2010
  end-page: 727
  ident: CR18
  article-title: Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: Comparison to FDG-PET
  publication-title: J. Neurol.
  doi: 10.1007/s00415-009-5396-8
– volume: 12
  start-page: 212
  year: 2020
  ident: CR49
  article-title: The validation of multifactor model of plasma Aβ42 and total-tau in combination with MoCA for diagnosing probable Alzheimer disease
  publication-title: Front. Aging Neurosci.
  doi: 10.3389/fnagi.2020.00212
– volume: 43
  start-page: 741
  year: 2014
  end-page: 743
  ident: CR14
  article-title: The importance of detecting and managing comorbidities in people with dementia?
  publication-title: Age Ageing
  doi: 10.1093/ageing/afu101
– volume: 11
  start-page: 111
  year: 2019
  ident: CR32
  article-title: Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early-stage Alzheimer’s disease
  publication-title: Alzheimers Res. Therapy
  doi: 10.1186/s13195-019-0566-0
– volume: 1
  start-page: 441
  year: 2010
  end-page: 446
  ident: CR47
  article-title: Obstructive sleep apnea syndrome in the Sao Paulo epidemiologic sleep study
  publication-title: Sleep Med.
  doi: 10.1016/j.sleep.2009.10.005
– volume: 66
  start-page: 190
  year: 2009
  end-page: 199
  ident: CR24
  article-title: A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease
  publication-title: Arch. Neurol.
  doi: 10.1001/archneurol.2008.565
– volume: 119
  start-page: 445
  year: 2019
  end-page: 452
  ident: CR22
  article-title: CSF biomarkers and amyloid PET: Concordance and diagnostic accuracy in A MCI cohort
  publication-title: Acta Neurol. Belg.
  doi: 10.1007/s13760-019-01112-8
– volume: 17
  start-page: 205
  year: 2017
  ident: CR13
  article-title: Risk factors for dementia in the ninth decade of life and beyond: A study of The Lothian birth cohort 1921
  publication-title: BMC Psychiatry
  doi: 10.1186/s12888-017-1366-3
– volume: 5
  start-page: 735
  year: 2006
  end-page: 741
  ident: CR9
  article-title: Risk score for the prediction of dementia risk in 20 years among middle aged people: A longitudinal, populationbased study
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(06)70537-3
– volume: 92
  start-page: 35
  year: 2016
  end-page: 40
  ident: CR7
  article-title: Preventing delirium in dementia: Managing risk factors
  publication-title: Maturitas
  doi: 10.1016/j.maturitas.2016.07.007
– volume: 3
  start-page: 186
  year: 2007
  end-page: 191
  ident: CR3
  article-title: Forecasting the global burden of Alzheimer’s disease
  publication-title: Alzheimers Dement.
  doi: 10.1016/j.jalz.2007.04.381
– volume: 26
  start-page: 10218
  year: 2020
  ident: CR35
  article-title: Nanoparticle-states based immunomagnetic assay of plasma biomarkers for differentiating dementia and prodromal of Alzheimer's disease—A cross-validation study
  publication-title: Nanomed. Nanotechnol. Biol. Med.
– volume: 73
  start-page: 1157
  year: 2020
  end-page: 1166
  ident: CR4
  article-title: The prevalence of dementia: A systematic review and meta-analysis
  publication-title: J. Alzheimers Dis.
  doi: 10.3233/JAD-191092
– volume: 366
  start-page: 2112
  year: 2005
  end-page: 2117
  ident: CR2
  article-title: Global prevalence of dementia: A Delphi consensus study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)67889-0
– volume: 8
  start-page: 1006
  year: 2009
  end-page: 1018
  ident: CR45
  article-title: Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: A systematic review and meta-analysis
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(09)70236-4
– volume: 18
  start-page: 388
  year: 2017
  end-page: 395
  ident: CR12
  article-title: Risk factors for mild cognitive impairment, dementia and mortality: The Sydney memory and ageing study
  publication-title: J. Am. Med. Dir. Assoc.
  doi: 10.1016/j.jamda.2016.10.014
– volume: 123
  start-page: 294
  year: 2007
  end-page: 304
  ident: CR26
  article-title: Counting of single prion particles bound to a capture-antibody surface (surface-FIDA)
  publication-title: Vet. Microbiol.
  doi: 10.1016/j.vetmic.2007.04.001
– volume: 13
  start-page: 657794
  year: 2021
  ident: CR34
  article-title: The role of plasma neurofilament light protein for assessing cognitive impairment in patients with end-stage renal disease
  publication-title: Front. Aging Neurosci.
  doi: 10.3389/fnagi.2021.657794
– volume: 27
  start-page: 904
  year: 2006
  end-page: 905
  ident: CR40
  article-title: Plasma levels of beta-amyloid (1–42) in Alzheimer's disease and mild cognitive impairment
  publication-title: Neurobiol. Aging
  doi: 10.1016/j.neurobiolaging.2006.03.004
– volume: 43
  start-page: 1220
  year: 2020
  end-page: 1232
  ident: CR39
  article-title: Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia: A population-based cohort study
  publication-title: Brain
– volume: 9
  start-page: 65
  year: 2019
  ident: CR20
  article-title: The who, when, why, and how of PET amyloid imaging in management of Alzheimer’s disease-review of literature and interesting images
  publication-title: Diagnostics
  doi: 10.3390/diagnostics9020065
– volume: 21
  start-page: 769
  year: 2010
  end-page: 773
  ident: CR25
  article-title: Comparison of conventional ELISA with electrochemiluminescence technology for detection of amyloid-β in plasma
  publication-title: J. Alzheimer’s Dis.
  doi: 10.3233/JAD-2010-100456
– volume: 11
  start-page: 222
  year: 2019
  ident: CR36
  article-title: Age-dependent relationship between plasma Aβ40 And Aβ42 and total tau levels in cognitively normal subjects
  publication-title: Front. Aging Neurosci.
  doi: 10.3389/fnagi.2019.00222
– volume: 1750
  start-page: 203
  year: 2018
  end-page: 212
  ident: CR19
  article-title: Amyloid PET imaging: Standardization and integration with other Alzheimer's disease biomarkers
  publication-title: Methods Mol. Biol.
  doi: 10.1007/978-1-4939-7704-8_13
– volume: 92
  start-page: 1044
  year: 2011
  end-page: 1052
  ident: CR5
  article-title: Aerobic exercise to improve cognitive function in adults with neurological disorders: A systematic review
  publication-title: Arch. Phys. Med. Rehabil.
  doi: 10.1016/j.apmr.2011.01.021
– volume: 62
  start-page: 1857
  year: 2018
  end-page: 1863
  ident: CR41
  article-title: Plasma amyloid-β (Aβ42) correlates with cerebrospinal fluid Aβ42 in Alzheimer's disease
  publication-title: J. Alzheimers Dis.
  doi: 10.3233/JAD-170784
– volume: 21
  start-page: 477
  year: 2011
  end-page: 480
  ident: CR29
  article-title: Multi-channel SQUID-based ultrahigh-sensitivity in-vitro detections for bio-markers of Alzheimer’s disease via immunomagnetic reduction
  publication-title: IEEE Trans. Appl. Supercond.
  doi: 10.1109/TASC.2010.2087304
– volume: 13
  start-page: 788
  year: 2014
  end-page: 794
  ident: CR11
  article-title: Potential for primary prevention of Alzheimer’s disease: An of population-based data
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(14)70136-X
– volume: 10
  start-page: 1144
  year: 2019
  ident: CR44
  article-title: Subtyping of circulating exosome-bound amyloid β reflects brain plaque deposition
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-019-09030-2
– volume: 19
  start-page: 659
  year: 2019
  ident: CR8
  article-title: Physical exercise for prevention of dementia (EPD) study: Background, design and methods
  publication-title: BMC Public Health
  doi: 10.1186/s12889-019-7027-3
– volume: 4
  start-page: 6446
  year: 2014
  end-page: 6511
  ident: CR28
  article-title: CSF and plasma amyloid-β temporal profiles and relationships with neurological status and mortality after severe traumatic brain injury
  publication-title: Sci. Rep.
  doi: 10.1038/srep06446
– volume: 423
  start-page: 697
  year: 2012
  end-page: 702
  ident: CR37
  article-title: Plasma amyloid-β oligomers level is a biomarker for Alzheimer's disease diagnosis
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2012.06.017
– volume: 13
  start-page: 1
  year: 2013
  end-page: 5
  ident: CR1
  article-title: A commentary on studies presenting projections of the future prevalence of dementia
  publication-title: BMC Public Health
  doi: 10.1186/1471-2458-13-1
– volume: 13
  start-page: e0196214
  year: 2018
  ident: CR17
  article-title: Development and validation of a dementia screening tool for care in Taiwan: Brain health test
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0196214
– volume: 20
  start-page: 498
  year: 2018
  end-page: 503
  ident: CR33
  article-title: Plasma β-amyloids and tau proteins in patients with vascular cognitive impairment
  publication-title: Neuromol. Med.
  doi: 10.1007/s12017-018-8513-y
– volume: 8
  start-page: 144
  year: 2016
  ident: CR6
  article-title: Nutrition and dementia: Evidence for preventive approaches?
  publication-title: Nutrients
  doi: 10.3390/nu8030144
– volume: 10
  start-page: 175
  year: 2018
  ident: CR31
  article-title: The relation between brain amyloid deposition, cortical atrophy, and plasma biomarkers in amnesic mild cognitive impairment and Alzheimer’s disease
  publication-title: Front. Aging Neurosci.
  doi: 10.3389/fnagi.2018.00175
– volume: 840
  start-page: 1
  year: 2014
  end-page: 9
  ident: CR27
  article-title: Detection and quantification of plasma amyloid-β by selected reaction monitoring mass spectrometry
  publication-title: Anal. Chim. Acta
  doi: 10.1016/j.aca.2014.06.024
– volume: 74
  start-page: 782
  year: 2019
  end-page: 790
  ident: CR46
  article-title: Cognitive impairment in CKD: Pathophysiology, management, and prevention
  publication-title: Am. J. Kidney Dis.
  doi: 10.1053/j.ajkd.2019.05.017
– volume: 108
  start-page: 754
  year: 2009
  end-page: 764
  ident: CR10
  article-title: Risk factors for dementia
  publication-title: Formos. Med. Assoc.
  doi: 10.1016/S0929-6646(09)60402-2
– volume: 63
  start-page: 828
  year: 2004
  ident: 5177_CR38
  publication-title: Neurology
  doi: 10.1212/01.WNL.0000137040.64252.ED
– volume: 1750
  start-page: 203
  year: 2018
  ident: 5177_CR19
  publication-title: Methods Mol. Biol.
  doi: 10.1007/978-1-4939-7704-8_13
– volume: 366
  start-page: 2112
  year: 2005
  ident: 5177_CR2
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)67889-0
– volume: 92
  start-page: 1044
  year: 2011
  ident: 5177_CR5
  publication-title: Arch. Phys. Med. Rehabil.
  doi: 10.1016/j.apmr.2011.01.021
– volume: 20
  start-page: 498
  year: 2018
  ident: 5177_CR33
  publication-title: Neuromol. Med.
  doi: 10.1007/s12017-018-8513-y
– volume: 10
  start-page: 175
  year: 2018
  ident: 5177_CR31
  publication-title: Front. Aging Neurosci.
  doi: 10.3389/fnagi.2018.00175
– volume: 8
  start-page: 1006
  year: 2009
  ident: 5177_CR45
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(09)70236-4
– volume: 7
  start-page: 2150
  year: 2020
  ident: 5177_CR23
  publication-title: Ann. Clin. Transl. Neurol.
  doi: 10.1002/acn3.51195
– volume: 10
  start-page: 1144
  year: 2019
  ident: 5177_CR44
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-019-09030-2
– volume: 119
  start-page: 445
  year: 2019
  ident: 5177_CR22
  publication-title: Acta Neurol. Belg.
  doi: 10.1007/s13760-019-01112-8
– volume: 85
  start-page: 1240
  year: 2015
  ident: 5177_CR21
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000001991
– volume: 123
  start-page: 294
  year: 2007
  ident: 5177_CR26
  publication-title: Vet. Microbiol.
  doi: 10.1016/j.vetmic.2007.04.001
– volume: 171
  start-page: 250
  year: 2016
  ident: 5177_CR15
  publication-title: Neuropsychiatr. Genet.
– volume: 5
  start-page: 735
  year: 2006
  ident: 5177_CR9
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(06)70537-3
– volume: 74
  start-page: 782
  year: 2019
  ident: 5177_CR46
  publication-title: Am. J. Kidney Dis.
  doi: 10.1053/j.ajkd.2019.05.017
– volume: 21
  start-page: 769
  year: 2010
  ident: 5177_CR25
  publication-title: J. Alzheimer’s Dis.
  doi: 10.3233/JAD-2010-100456
– volume: 257
  start-page: 721
  year: 2010
  ident: 5177_CR18
  publication-title: J. Neurol.
  doi: 10.1007/s00415-009-5396-8
– volume: 19
  start-page: 659
  year: 2019
  ident: 5177_CR8
  publication-title: BMC Public Health
  doi: 10.1186/s12889-019-7027-3
– volume: 92
  start-page: 35
  year: 2016
  ident: 5177_CR7
  publication-title: Maturitas
  doi: 10.1016/j.maturitas.2016.07.007
– volume: 18
  start-page: 388
  year: 2017
  ident: 5177_CR12
  publication-title: J. Am. Med. Dir. Assoc.
  doi: 10.1016/j.jamda.2016.10.014
– volume: 4
  start-page: 6446
  year: 2014
  ident: 5177_CR28
  publication-title: Sci. Rep.
  doi: 10.1038/srep06446
– volume: 43
  start-page: 1220
  year: 2020
  ident: 5177_CR39
  publication-title: Brain
  doi: 10.1093/brain/awaa054
– volume: 1
  start-page: 441
  year: 2010
  ident: 5177_CR47
  publication-title: Sleep Med.
  doi: 10.1016/j.sleep.2009.10.005
– volume: 3
  start-page: 186
  year: 2007
  ident: 5177_CR3
  publication-title: Alzheimers Dement.
  doi: 10.1016/j.jalz.2007.04.381
– volume: 66
  start-page: 190
  year: 2009
  ident: 5177_CR24
  publication-title: Arch. Neurol.
  doi: 10.1001/archneurol.2008.565
– volume: 840
  start-page: 1
  year: 2014
  ident: 5177_CR27
  publication-title: Anal. Chim. Acta
  doi: 10.1016/j.aca.2014.06.024
– volume: 13
  start-page: 657794
  year: 2021
  ident: 5177_CR34
  publication-title: Front. Aging Neurosci.
  doi: 10.3389/fnagi.2021.657794
– volume: 26
  start-page: 10218
  year: 2020
  ident: 5177_CR35
  publication-title: Nanomed. Nanotechnol. Biol. Med.
– volume: 9
  start-page: 65
  year: 2019
  ident: 5177_CR20
  publication-title: Diagnostics
  doi: 10.3390/diagnostics9020065
– volume: 21
  start-page: 477
  year: 2011
  ident: 5177_CR29
  publication-title: IEEE Trans. Appl. Supercond.
  doi: 10.1109/TASC.2010.2087304
– volume: 12
  start-page: 212
  year: 2020
  ident: 5177_CR49
  publication-title: Front. Aging Neurosci.
  doi: 10.3389/fnagi.2020.00212
– volume: 62
  start-page: 1857
  year: 2018
  ident: 5177_CR41
  publication-title: J. Alzheimers Dis.
  doi: 10.3233/JAD-170784
– volume: 13
  start-page: e0196214
  year: 2018
  ident: 5177_CR17
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0196214
– volume: 8
  start-page: 144
  year: 2016
  ident: 5177_CR6
  publication-title: Nutrients
  doi: 10.3390/nu8030144
– volume: 13
  start-page: 788
  year: 2014
  ident: 5177_CR11
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(14)70136-X
– volume: 73
  start-page: 1157
  year: 2020
  ident: 5177_CR4
  publication-title: J. Alzheimers Dis.
  doi: 10.3233/JAD-191092
– volume: 9
  start-page: 226
  year: 2017
  ident: 5177_CR42
  publication-title: Front. Aging Neurosci.
  doi: 10.3389/fnagi.2017.00226
– volume: 13
  start-page: 1
  year: 2013
  ident: 5177_CR1
  publication-title: BMC Public Health
  doi: 10.1186/1471-2458-13-1
– volume: 5
  start-page: 830
  year: 2014
  ident: 5177_CR30
  publication-title: ACS Chem. Neurosci.
  doi: 10.1021/cn500101j
– volume: 108
  start-page: 754
  year: 2009
  ident: 5177_CR10
  publication-title: Formos. Med. Assoc.
  doi: 10.1016/S0929-6646(09)60402-2
– volume: 11
  start-page: 111
  year: 2019
  ident: 5177_CR32
  publication-title: Alzheimers Res. Therapy
  doi: 10.1186/s13195-019-0566-0
– volume: 11
  start-page: 222
  year: 2019
  ident: 5177_CR36
  publication-title: Front. Aging Neurosci.
  doi: 10.3389/fnagi.2019.00222
– volume: 27
  start-page: 904
  year: 2006
  ident: 5177_CR40
  publication-title: Neurobiol. Aging
  doi: 10.1016/j.neurobiolaging.2006.03.004
– volume: 43
  start-page: 741
  year: 2014
  ident: 5177_CR14
  publication-title: Age Ageing
  doi: 10.1093/ageing/afu101
– volume: 5
  start-page: 13917
  year: 2015
  ident: 5177_CR48
  publication-title: Sci. Rep.
  doi: 10.1038/srep13917
– volume: 17
  start-page: 205
  year: 2017
  ident: 5177_CR13
  publication-title: BMC Psychiatry
  doi: 10.1186/s12888-017-1366-3
– volume: 423
  start-page: 697
  year: 2012
  ident: 5177_CR37
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2012.06.017
– volume: 21
  start-page: 1376
  year: 2021
  ident: 5177_CR43
  publication-title: ACS Chem. Neurosci.
  doi: 10.1021/acschemneuro.1c00010
– volume: 16
  start-page: 310
  year: 2021
  ident: 5177_CR16
  publication-title: Neural Regen. Res.
  doi: 10.4103/1673-5374.290898
SSID ssj0000529419
Score 2.397073
Snippet Subjects with comorbidities are at risk for neurodegeneration. There is a lack of a direct relationship between comorbidities and neurodegeneration. In this...
Abstract Subjects with comorbidities are at risk for neurodegeneration. There is a lack of a direct relationship between comorbidities and neurodegeneration....
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1192
SubjectTerms 631/378
692/499
692/53
692/617
692/699
Adult
Aged
Aged, 80 and over
Alzheimer's disease
Amyloid beta-Peptides - blood
Apnea
Biomarkers
Biomarkers - blood
Case-Control Studies
Cognition
Dementia
Dementia - blood
Dementia - etiology
Dementia disorders
Diabetes
Diabetes Complications - blood
Diabetes mellitus
End-stage renal disease
Female
Genetics
Humanities and Social Sciences
Humans
Kidney diseases
Kidney Failure, Chronic - blood
Kidney Failure, Chronic - complications
Male
Middle Aged
multidisciplinary
Neurodegeneration
Neurodegenerative diseases
Peptide Fragments - blood
Plasma
Plasma levels
Risk Assessment
Science
Science (multidisciplinary)
Sleep apnea
Sleep Apnea, Obstructive - blood
Sleep Apnea, Obstructive - complications
Sleep disorders
Stroke
Stroke - blood
Stroke - complications
Tau protein
tau Proteins - blood
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJSQuiDcpLTISN7AaP2LHR1q1qpDgRKVekOXYDlRaslWze2h_PTN2NnR5XrjGk8iaR_zZM_6GkNcy6TqpPrHGSMWUt4J1SvQsely8lOiSxLvDHz7q0zP1_rw5v9XqC2vCCj1wUdxBCEbFWnuuewtgXvm6VTz6XraANHgf8e9b2_rWZqqweguruJ1uydSyPRhhpcLbZLD3Qloqw262VqJM2P87lPlrseRPGdO8EJ08IPcnBEnflZk_JHfS8IjcLT0lrx-Tz5s-oXTZ00vAxt88xTv2WIZzNVJMUeMp3fCFIlMxxdJylIz5mPDCgwCdS4oW13RATLug47rDA5vxCTk7Of50dMqmHgosABZbsQZiuLHJyqCk4dzGxHXXcezuy0PXGa2C0VEEraM30tS-gYgE8U6oiDqUT8nOsBzSc0KF7QFtyaBVG5T13tomAaBpJXw5RNNXhG_06cJEMI59LhYuJ7pl64oNHNjAZRu4m4q8md-5LPQaf5U-RDPNkkiNnR-Aw7jJYdy_HKYiexsjuyleRyc0wKS2EaqpyKt5GCIN0yd-SMt1kQG8JoypyLPiE_NMJMBqwMKqImbLW7amuj0yXHzNbN6tabVtbEXebvzqx7T-rIrd_6GKF-SeyAHBmVB7ZGd1tU77gLFW3cscTt8BL7MgyA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkLouUVaJGRuIHVxHbs-IQAUVWV4ESlvSDLsZ1SaUmWze6h_fXMOI9qefQaTyLHM-P5PDOeIeSNiCqPsoms1EIy6QxnteQNCw6Nl-R1FHh3-MtXdXouzxblYnS49WNa5bQnpo06dB595MdcgSGrSi7L96tfDLtGYXR1bKFxl9wrAIlg6wa90LOPBaNYsjDjXZlcVMc92Cu8UwYnMCxOpdn1jj1KZfv_hTX_Tpn8I26azNHJI_JwxJH0w8D4fXIntgfk_tBZ8uox-T51C6VdQ1eAkH86ijftMRln3VMMVKOvrr2gWK-YYoI5UobkLLx0QEDnxKLlFW0R2S5pv63RbdM_Iecnn799OmVjJwXmAZFtWAmaXJpohJdCw0qFWKi6LrDHb-HrWivptQrcKxWcFjp3JeglkNdcBlxD8ZTstV0bnxPKTQOYS3glKy-Nc8aUEWBNJeDLPugmI8W0ntaPZcax28XSpnC3qOzAAws8sIkH9jojb-d3VkORjVupPyKbZkoskJ0edOsLO-qb9V7LkCtXqMbAGVC6vJJFcI2o8J-bkJHDicl21Nre3shYRl7Pw6BvGERxbey2Aw2gNq51Rp4NMjHPRAC4BkQsM6J3pGVnqrsj7eWPVNO70pUypcnIu0mubqb1_6V4cftfvCQPeBL1gnF5SPY26208Agy1qV8lRfkNTQkYgg
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEB_OE8EX8duep0TwTaubjybNg4iKxyHokwv3IiFN07uDtXtud-H2_npn0nZldRV8bSclnQ_ml8wXwHMZ9SSqJuaFkSpX3oq8UqLJa0_OS4kqSqod_vxFH0_Vp5PiZA_GcUcDA7udRzuaJzVdzF5d_li_RYN_05eMl687dEJUKIbHKuo4ZfKra3A9xYsolW-A-32vb2EVt0PtzO6lW_4ptfHfhT3_TKH8LY6a3NPRbbg14Er2rleEO7AX27two580ub4H38bpoWzesAtEzN89o8p7Ss5ZdIwC13R3154y6l_MKOGcKOt0eXjukYBtEo1ma9YS0p2xblXRNU53H6ZHH79-OM6HyQp5QIS2zAu07MJGK4OShnNbR66ritPMXx6qymgVjK5F0Lr2RpqJL9BOkbwSqiYeygew387b-AiYsA1iMBm0KoOy3ltbRIQ5pcQvh9o0GfCRny4Mbcdp-sXMpfC3LF0vA4cycEkG7iqDF5s1F33TjX9SvycxbSipYXZ6MF-cusH-XAhG1RPtuW4sngmVn5SK176RJf1zU2dwOArZjUrohEbwVBZCFRk827xG-6Ogim_jfNXTIIoTxmTwsNeJzU4kgm1EyCoDs6UtW1vdftOen6Ue36UptS1sBi9Hvfq1rb-z4uD_yB_DTZFUn-dCHcL-crGKTxBjLaunyXB-AjpNIIU
  priority: 102
  providerName: Scholars Portal
Title Evidence of plasma biomarkers indicating high risk of dementia in cognitively normal subjects
URI https://link.springer.com/article/10.1038/s41598-022-05177-z
https://www.ncbi.nlm.nih.gov/pubmed/35075194
https://www.proquest.com/docview/2622385245
https://www.proquest.com/docview/2622658277
https://pubmed.ncbi.nlm.nih.gov/PMC8786959
https://doaj.org/article/cc74d06a16f94954a0841daf380571fd
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9swED_alMFexr7nrQsa7G0ziyVZH49paCmBlrGtkJchZFluC5lT4uSh_et3kj9Gtm6wFxvss5F1d9ZP9wnwnnkx8bzyaS4ZT7nVNC04rdLShsWL08KzkDt8di5OL_h8kS_2gPa5MDFoP5a0jL_pPjrsU4MLTUgGw61TqCol07t9OFASf78jOJhO51_ng2Ul-K54prsMmQlT9zy8swrFYv33Icw_AyV_85bGRejkMTzq0COZtuN9Anu-fgoP2n6St8_ge98jlKwqcoO4-IclIb8-hOCsGxLc08FCV1-SUKWYhLDyQFlGE-G1RQIyhBMtb0kd8OySNNsiGGua53Bxcvxtdpp2_RNShzhsk-aov7n2mjnOZJbp0meiKLLQ2TdzRSEFd1KU1AlRWsnkxOaojUheUF6GOWQvYFSvav8KCNUVIi3mBFeOa2u1zj2CGcXwza6UVQJZP5_GdcXFQ4-LpYlObqZMywODPDCRB-YugQ_DMzdtaY1_Uh8FNg2UoSx2vLBaX5pOTIxzkpcTYTNRadz5cTtRPCttxVT45qpM4LBnsul0tTFUIERSOeV5Au-G26hlwXVia7_atjSI1aiUCbxsZWIYCUNIjTiYJyB3pGVnqLt36uurWMlbSSV0rhP42MvVr2H9fSpe_x_5G3hIo-hnKeWHMNqst_4tIqlNMYZ9uZDjToHwfHR8_vkLXp2J2ThaJ_B4xtVPn2QddA
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrRBcEG8CBYwEJ4ia2I4dHypEodWWtiuEWqkXFBzbKZWW7LLZFdr-OH4bnryq5dFbr_Ekcjxjz-d5ArxkTkSOFy5MJOMh14qGOadFaDUqL05zxzB3-HAkhsf840lysga_ulwYDKvszsT6oLYTgzbyTSq8IksTypO30x8hdo1C72rXQkO3rRXsVl1irE3s2HfLn_4KV23tffD8fkXp7s7R-2HYdhkIjUcr8zDxUp4op5jhTMaxsi4WeR5j_9vY5LkU3EhhqRHCaslkpBMvs548p9wmVHHmv3sN1jkaUAawvr0z-vS5t_KgH43Hqs3WiVi6WXmNiVlt_g6I5bFkeL6iEevGAf9Cu38Hbf7hua0V4u5tuNUiWfKuEb07sObKu3C96W25vAdfun6lZFKQqcfo3zXBXH8MB5pVBF3laC0sTwlWTCYY4o6UtjZXnmlPQPrQpvGSlIitx6Ra5Gg4qu7D8ZWs8gMYlJPSPQJCVeFRHzOCp4YrrZVKnAdWKfNfNlYWAcTdemamLXSO_TbGWe1wZ2nW8CDzPMhqHmTnAbzu35k2ZT4upd5GNvWUWKK7fjCZnWbtjs-MkdxGQseiUP4WynWU8tjqgqX4z4UNYKNjctaeG1V2IeUBvOiH_Y5HN44u3WTR0HjcSKUM4GEjE_1MmIf3HpPzAOSKtKxMdXWkPPtWVxVPZSpUogJ408nVxbT-vxSPL_-L53BjeHR4kB3sjfafwE1ai30cUr4Bg_ls4Z56RDfPn7XbhsDXq96pvwGeIFmG
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKKxAXxJtAASPBCaJNbMeODxWitKuWwqpCVOoFpY7tlEpLdtnsCm1_Ir-Kmbyq5dFbr5vZyPHMeD7Pk5CX3MvIi8KHieIiFEazMBesCJ1B4yVY7jnWDn8ayb0j8eE4OV4jv7paGEyr7M7E-qB2E4s-8gGTYMjShIlkULRpEYc7w7fTHyFOkMJIazdOw7RjFtxW3W6sLfI48MufcJ2rtvZ3gPevGBvufnm_F7YTB0ILyGUeJiDxifaaW8FVHGvnY5nnMc7CjW2eKymsko5ZKZ1RXEUmAfkF8pwJlzAtOLz3GtlQYPXhIrixvTs6_Nx7fDCmJmLdVu5EPB1UYD2xwg3ug9gqS4XnK9axHiLwL-T7dwLnH1Hc2jgOb5NbLaql7xoxvEPWfHmXXG_mXC7vka_d7FI6KegU8Pp3Q7HuH1ODZhXFsDl6DstTit2TKaa7I6WrXZdnBghon-Y0XtIScfaYVoscnUjVfXJ0Jbv8gKyXk9I_IpTpAhAgt1KkVmhjtE48gKyUw5utU0VA4m4_M9s2PcfZG-OsDr7zNGt4kAEPspoH2XlAXvf_mTYtPy6l3kY29ZTYrrv-YTI7zVrtz6xVwkXSxLLQcCMVJkpF7EzBU_zmwgVks2Ny1p4hVXYh8QF50T8G7ceQjin9ZNHQAIZkSgXkYSMT_Uo4QH3A5yIgakVaVpa6-qQ8-1Z3GE9VKnWiA_Kmk6uLZf1_Kx5f_hXPyQ3Q2Ozj_ujgCbnJaqmPQyY2yfp8tvBPAdzN82et1lByctWK-hsts13K
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evidence+of+plasma+biomarkers+indicating+high+risk+of+dementia+in+cognitively+normal+subjects&rft.jtitle=Scientific+reports&rft.au=Pai%2C+Ming-Chyi&rft.au=Wu%2C+Chau-Chung&rft.au=Hou%2C+Yi-Chou&rft.au=Jeng%2C+Jiann-Shing&rft.date=2022-01-24&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2045-2322&rft.volume=12&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-022-05177-z&rft.externalDocID=10_1038_s41598_022_05177_z
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon